




		<b>EMLc</b>	ATC codes: <b>L01BA01</b>
<b>Indication</b>	Osteosarcoma of bone and articular cartilage of unspecified sites	ICD11 code: <b>2C21.Z</b>	
<b>INN</b>	Methotrexate		
<b>Medicine type</b>	Chemical agent		
<b>List type</b>	Complementary (EML) (EMLc)		
<b>Formulations</b>	Parenteral > General injections > IV: 50 mg in vial (as sodium salt) ; 50 mg per 2 mL ; 1000 mg per 10 mL concentrated injection Oral > Solid: 2.5 mg (as sodium salt)		
<b>EML status history</b>	First added in 2015 ( <a href="#">TRS 994</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
<b>Tags</b>	<a href="#">Cancer</a>		
<b>Wikipedia</b>	<a href="#">Methotrexate</a> 		
<b>DrugBank</b>	<a href="#">Methotrexate</a> 		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of additional dose forms of methotrexate (Injection: 50 mg/2 mL and Concentrated injection: 1000 mg/10 mL) to the EML and EMLc.

[Expert Committee report](#) 

